Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Milman, C. B. Svendsen, C. M. Burton, M. Iversen, R. Videbaek, J. Carlsen (Copenhagen, Denmark). Acute vasoresponsiveness to inhaled nitric oxide in sarcoidosis-associated pulmonary hypertension. Eur Respir J 2008; 32: Suppl. 52, 3437

Member's Comments

No comment yet.

Related content which might interest you: Influence of inhaled nitric oxide on plasma endothelin-1 in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003 Nitric oxide vs prostacyclin in chronic high-flow pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002 Comparative effects of inhaled nitric oxide and aerosolized iloprost during vasoreactivity testing in chronic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005 Infused nitric oxide in experimental pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 348s Year: 2007 Exhaled nitric oxide in patients with idiopathic pulmonary fibrosis and pulmonary hypertension Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 Inhaled nitric oxide (NO) for vasoreactivity testing in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003 Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006 Nitric oxide in acute testing in patients with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004 Combination of inhaled nitric oxide and an endothelinA-receptor antagonist in acute pulmonary thromboembolism Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003 Exhaled nitric oxide levels in patients with pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Feasibility of home treatment with inhaled nitric oxide for primary pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Fractional exhaled nitric oxide in pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction Source: Eur Respir J 2003; 21: 19-24 Year: 2003 The effect of inhaled nitric oxide on the cardiac performance in patients with hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003 Evaluation of exhaled nitric oxide in idiopathic interstitial lung diseases Source: International Congress 2015 – IIPs: orphan Year: 2015 Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1386-1395 Year: 2016 Tolerance of long term nitric oxide treatment in severe arterial pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002 Effect of the Asp298 variant of endothelial nitric oxide synthase on acute pulmonary vasodilator testing response in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Fractional exhaled nitric oxide in chronic obstructive pulmonary disease Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015 Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016